GlassScriptPhysician profile
Yara E Tovar
NPI 1740488279
$2,005.13
in general payments reported to CMS, 2019-2025
20 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $132 · 2021: $345 · 2022: $184 · 2023: $381 · 2024: $188 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.87 |
| Education | $205.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $665.13 | 2020-2025 | Wegovy, Ozempic |
| W. L. Gore & Associates, INC. | $277.11 | 2022-2023 | Gore Enform Preperitoneal Biomaterial |
| Lilly USA, LLC | $129.37 | 2019-2021 | |
| Davol INC. | $125.99 | 2023 | |
| Horizon Therapeutics Plc | $118.09 | 2021 | |
| Abbott Laboratories | $116.56 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $114.55 | 2022-2025 | Minimed 780g |
| Ethicon US, LLC | $82.14 | 2023 | Echelon Flex |
| Dexcom, INC. | $73.16 | 2021-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $49.35 | 2024-2025 | Yorvipath |
| Becton, Dickinson and Company | $45.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.05 | 2019 | |
| Zealand Pharma US, INC. | $33.96 | 2021 | |
| Valeritas, INC. | $25.44 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $23.27 | 2025 | Imcivree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $19.56 | 2025 | Twiist |
| Insulet Corporation | $19.38 | 2021 | |
| Medtronic Minimed, INC. | $14.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.04 | 2021 | |
| Tandem Diabetes Care, INC. | $13.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yara Tovar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.